Epithelial phenotypic changes detect cyclosporine in vivo nephrotoxicity at a reversible stage

Transplantation

Volumn 92, Issue 9, 2011, Pages 993-998

  Galichon, Pierre ^a,b,c   Vittoz, Nathalie ^a,b,c   Xu Dubois, Yi Chun ^a,c   Cornaire, Emilie ^a   Vandermeersch, Sophie ^a   Mesnard, Laurent ^a,b,c   Hertig, Alexandre ^a,b,c   Rondeau, Eric ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Biomarker; Chronic allograft dysfunction; Cyclosporine nephrotoxicity

Indexed keywords

BETA CATENIN; BOSENTAN; COLLAGEN TYPE 3; CYCLOSPORIN A; HEAT SHOCK PROTEIN 47; IRBESARTAN; MESSENGER RNA; RAPAMYCIN; TRANSCRIPTION FACTOR SNAIL; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC REGULATION; HISTOLOGY; IN VIVO STUDY; MALE; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; TREATMENT FAILURE;

ACUTE KIDNEY INJURY; ANGIOTENSIN II; ANIMALS; BETA CATENIN; BIOLOGICAL MARKERS; COLLAGEN TYPE III; CYCLOSPORINE; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; HSP47 HEAT-SHOCK PROTEINS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; MODELS, ANIMAL; PHENOTYPE; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION FACTORS; UP-REGULATION; VIMENTIN;

EID: 80055021561     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31822fa495     Document Type: Article

References (33)

1. Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978; 2: 1323.
2. Myers BD, Ross J, Newton L, et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699.
3. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481.
4. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
5. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
6. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibodymediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68.
7. Gourishankar S, Leduc R, Connett J, et al. Pathological and clinical characterization of the 'troubled transplant': Data from the DeKAF study. Am J Transplant 2010; 10: 324.
8. Matas AJ, Leduc R, Rush D, et al. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses ofCANor CR: Preliminary data from the DeKAF study. Am J Transplant 2010; 10: 315.
9. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518.
10. Hertig A, Anglicheau D, Verine J, et al. Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol 2008; 19: 1584.
11. Hertig A, Verine J, Mougenot B, et al. Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transplant 2006; 6: 2937.
12. Galichon P, Hertig A. Epithelial to mesenchymal transition as a biomarker in renal fibrosis: Are we ready for the bedside? Fibrogenesis Tissue Repair 2011; 4: 11.
13. Zeisberg M, Duffield JS. Resolved: EMT produces fibroblasts in the kidney. J Am Soc Nephrol 2010; 21: 1247.
14. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420.
15. Djamali A, Reese S, Yracheta J, et al. Epithelial-to-mesenchymal transition and oxidative stress in chronic allograft nephropathy. Am J Transplant 2005; 5: 500.
16. Djamali A, Vidyasagar A, Adulla M, et al. Nox-2 is a modulator of fibrogenesis in kidney allografts. Am J Transplant 2009; 9: 74.
17. Robertson H, Ali S, McDonnell BJ, et al. Chronic renal allograft dysfunction: The role of T cell-mediated tubular epithelial to mesenchymal cell transition. J Am Soc Nephrol 2004; 15: 390.
18. Vongwiwatana A, Tasanarong A, Rayner DC, et al. Epithelial to mesenchymal transition during late deterioration of human kidney transplants: The role of tubular cells in fibrogenesis.AmJ Transplant 2005; 5: 1367.
19. de Matos AC, Câmara NO, Tonato EJ, et al. Vimentin expression and myofibroblast infiltration are early markers of renal dysfunction in kidney transplantation: An early stage of chronic allograft dysfunction? Transplant Proc 2010; 42: 3482.
20. Slattery C, Campbell E, McMorrow T, et al. Cyclosporine A-induced renal fibrosis:Arole for epithelial-mesenchymal transition.AmJ Pathol 2005; 167: 395.
21. Pallet N, Bouvier N, Bendjallabah A, et al. Cyclosporine-induced endoplasmic reticulum stress triggers tubular phenotypic changes and death. Am J Transplant 2008; 8: 2283.
22. Conger JD, Kim GE, Robinette JB. Effects of ANG II, ETA, and TxA2 receptor antagonists on cyclosporin A renal vasoconstriction. Am J Physiol 1994; 267(3 pt 2): F443.
23. Kopp JB, Klotman PE. Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol 1990; 1: 162.
24. Elzinga LW, Rosen S, Bennett WM. Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: Role of sodium intake. J AmSoc Nephrol 1993; 4: 214.
25. Hazzan M, Hertig A, Buob D, et al. Epithelial-to-mesenchymal transition predicts cyclosporine nephrotoxicity in renal transplant recipients. J Am Soc Nephrol 2011; 22: 1375.
26. Jevnikar AM, Mannon RB. Late kidney allograft loss: What we know about it, and what we can do about it. Clin J Am Soc Nephrol 2008; 3(suppl 2): S56.
27. Opelz G, Zeier M, Laux G, et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: A collaborative transplant study report. J Am Soc Nephrol 2006; 17: 3257.
28. Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993; 91: 2144.
29. Nakahama H. Stimulatory effect of cyclosporine A on endothelin secretion by a cultured renal epithelial cell line, LLC-PK1 cells. Eur J Pharmacol 1990; 180: 191.
30. Bagnato A, Rosanò L. Epithelial-mesenchymal transition in ovarian cancer progression: A crucial role for the endothelin axis. Cells Tissues Organs 2007; 185: 85.
31. Shi B, Cai M, Qian Y, et al. Additive immunosuppressive effect of hydroxycamptothecin and cyclosporine on rejection of heart transplantation in rats. Transplant Proc 2007; 39: 3429.
32. Lijkwan MA, Cooke DT, Martens JM, et al. Cyclosporine treatment of high dose and long duration reduces the severity of graft coronary artery disease in rodent cardiac allografts. J Heart Lung Transplant 2005; 24: 439.
33. Geerling RA, de Bruin RW, Scheringa M, et al. Suppression of acute rejection prevents graft arteriosclerosis after allogeneic aorta transplantation in the rat. Transplantation 1994; 58: 1258.